Literature DB >> 20923803

Dramatic improvement in pulmonary hypertension with rapamycin.

Jeffrey D Wessler1, Richard M Steingart, Gary K Schwartz, Ben-Gary Harvey, Wendy Schaffer.   

Abstract

This is a report of a 61-year-old woman with improved pulmonary arterial hypertension following treatment with rapamycin for an islet cell tumor of the pancreas with liver metastases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20923803     DOI： 10.1378/chest.09-2435

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


  8 in total

1.  PDGF enhances store-operated Ca2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells.

Authors:  Aiko Ogawa; Amy L Firth; Kimberly A Smith; Mary V Maliakal; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2011-10-26       Impact factor: 4.249

2.  Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.

Authors:  Yuhu He; Caojian Zuo; Daile Jia; Peiyuan Bai; Deping Kong; Di Chen; Guizhu Liu; Juanjuan Li; Yuanyang Wang; Guilin Chen; Shuai Yan; Bing Xiao; Jian Zhang; Lingjuan Piao; Yanli Li; Yi Deng; Bin Li; Philippe P Roux; Katrin I Andreasson; Richard M Breyer; Yunchao Su; Jian Wang; Ankang Lyu; Yujun Shen; Ying Yu
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

3.  Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.

Authors:  Amal Houssaini; Shariq Abid; Nathalie Mouraret; Feng Wan; Dominique Rideau; Mirna Saker; Elisabeth Marcos; Claire-Marie Tissot; Jean-Luc Dubois-Randé; Valérie Amsellem; Serge Adnot
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

Review 4.  Potential therapeutic effects of mTOR inhibition in atherosclerosis.

Authors:  Ammar Kurdi; Guido R Y De Meyer; Wim Martinet
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

Review 5.  mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target.

Authors:  Aleksandra Babicheva; Ayako Makino; Jason X-J Yuan
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

6.  Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension.

Authors:  Yinan Shi; Chenxin Gu; Tongtong Zhao; Yangfan Jia; Changlei Bao; Ang Luo; Qiang Guo; Ying Han; Jian Wang; Stephen M Black; Ankit A Desai; Haiyang Tang
Journal:  Front Pharmacol       Date:  2021-11-11       Impact factor: 5.988

7.  Differential Expression Profile of microRNAs and Tight Junction in the Lung Tissues of Rat With Mitomycin-C-Induced Pulmonary Veno-Occlusive Disease.

Authors:  Qing Song; Ping Chen; Shang-Jie Wu; Yan Chen; Yan Zhang
Journal:  Front Cardiovasc Med       Date:  2022-02-16

8.  Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells.

Authors:  Elena A Goncharova; Irene S Khavin; Dmitry A Goncharov; Vera P Krymskaya
Journal:  Respir Res       Date:  2012-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.